IPP Bureau
Vivimed Labs receives products approvals from Uzbekistan
By IPP Bureau - March 09, 2021
Vivimed strategy is to increase its share of Branded products in CIS Markets.
Glenmark signs on Rohit Sharma as brand ambassador of Candid Powder
By IPP Bureau - March 08, 2021
Candid Powder brand is a market-leader in its category, with a market share of 64% in the medicated powder category.
Aarti Speciality Chemicals receives PLI approval for pharmaceutical sector
By IPP Bureau - March 08, 2021
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Sun Pharma arm to acquire stake in WRS Bioproducts, Australia
By IPP Bureau - March 06, 2021
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
Lupin launches penicillamine tablets USP
By IPP Bureau - March 04, 2021
Penicillamine Tablets USP, 250 mg (RLD: Depen) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT December 2020).
COVAXIN demonstrates interim clinical efficacy of 81%
By IPP Bureau - March 04, 2021
Bharat Biotech expects to share further details of the trial results as additional data become available.
Merck FY20 sales up 8.6% euro 17.5 bn
By IPP Bureau - March 04, 2021
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
DSM increases price for polyamide 6 and 66 in EMEA
By IPP Bureau - March 02, 2021
The price increases are due to the rising costs of raw materials.
DSM secures victory in patent infringement litigation against Anhui Tiger
By IPP Bureau - March 02, 2021
Tiger can no longer make an important biotin intermediate using a DSM patented process.
Piramal Enterprises cashing in on opportunities: ICICI Securities
By IPP Bureau - March 02, 2021
PEL will explore the PLI scheme and apply if its beneficial.
.jpg "Bayer delivers robust performance despite pandemic")
Bayer delivers robust performance despite pandemic
By IPP Bureau - February 26, 2021
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
India approves PLI scheme for pharmaceuticals
By IPP Bureau - February 26, 2021
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
Government allocates over Rs. 10,000 Cr in PLI scheme for bulk drugs and medical devices: Gowda
By IPP Bureau - February 26, 2021
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
Granules India gets USFDA approval of acetaminophen, aspirin and caffeine tablets
By IPP Bureau - February 25, 2021
ranules now has a total of 38 ANDA approvals from US FDA.
Aurobindo Pharma to acquire 26% ownerships solar power companies
By IPP Bureau - February 24, 2021
The company will be holding 26% of the share capital in each of the solar power generating companies.
